Novo Nordisk's Price and Pill Playbook in a Shifting GLP-1 Arena

Novo Nordisk defends obesity drug franchise with new 7.2mg Wegovy dose and positive oral semaglutide data, despite stock slump and generic competition in India.

Novo Nordisk is deploying a multi-pronged strategy to defend its lucrative obesity drug franchise, even as its stock price reflects deep investor skepticism. The shares have shed roughly 28% since the start of the year, closing Friday at 32.06 euros—a stark contrast to their 52-week high above 70 euros. This decline underscores the mounting pressures from new generic competition and a fierce battle for market leadership.

The competitive landscape shifted fundamentally with the recent launch of the first low-cost GLP-1 generics in India, following key patent expirations for semaglutide. This incursion is forcing immediate price adjustments from the Danish pharmaceutical giant and poses a long-term threat to its dominant market share. The nervous reaction from major investors is palpable. Investment firm Bfsg LLC, for instance, slashed its position in Novo Nordisk by approximately 60% during the fourth quarter of 2025.

Despite these headwinds, the company's recent operational performance was robust. Its last quarterly report showed earnings per share of $1.01, comfortably beating analyst estimates of $0.90. Revenue also exceeded expectations, coming in at $12.43 billion.

To counter competitive threats, Novo Nordisk is aggressively pushing forward on several clinical and commercial fronts. Fresh data from the ORION study indicates its oral semaglutid outperforms Eli Lilly's rival drug Orforglipron (marketed as Foundayo) in both weight reduction and tolerability. This is a critical advantage as the market for oral GLP-1 therapies gains importance.

Simultaneously, the company has introduced a new 7.2-mg dosage of its injectable Wegovy in the United States, making it available nationwide. Priced at around $399 per month for self-payers, this is a deliberately low entry point aimed at price-sensitive patients and designed to secure share against Eli Lilly's Zepbound.

In Europe, Novo Nordisk has secured a significant logistical advantage. The European Medicines Agency (EMA) has relaxed storage requirements for Wegovy, permitting it to be transported for up to 48 hours at temperatures reaching 30 degrees Celsius. This flexibility greatly simplifies the crucial "last mile" delivery to pharmacies and online retailers, potentially easing supply bottlenecks.

All eyes are now on how these strategic moves will translate into financial results and market share preservation. Management will provide concrete figures on the business impact of the new generic competition when Novo Nordisk presents its next quarterly report on May 6, 2026. The company's ability to regain investor confidence hinges on the uptake of its new Wegovy dosage and whether its superior clinical data can meaningfully influence prescribing habits.